NCT02268474已完成不适用
Prospective, Randomized, Controlled Split-Face Study of the Excel V 532nm KTP Laser for the Treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea
Cutera Inc.2 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2014年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 22
- 试验地点
- 2
- 主要终点
- Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea
研究概览
简要总结
A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea.
Subjects will receive laser treatments and will be followed at 6 weeks post-final laser treatment.
详细描述
The purpose of this study is to evaluate the safety and efficacy of the 532nm KTP laser within the Cutera® Excel V system for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea as compared to a 595nm Pulse Dye Laser.
The objectives of this study are:
- To evaluate and compare the safety and efficacy of the laser treatments for Erythematotelangiectatic Rosacea and Papulopustular Rosacea at 6 weeks post final laser treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Females or Males, 20 to 80 years of age (inclusive).
- •Fitzpatrick Skin Type I - III.
- •Clinical diagnosis of Erythematotelangiectatic Rosacea and Papulopustular Rosacea.
- •Willing to refrain from using systemic corticosteroids or retinoids; or topical corticosteroids or retinoids on the treated area.
- •Must be able to read, understand and sign the Informed Consent Form.
- •Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
- •Wiling to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the face every day for the duration of the study, including the follow-up period.
- •Willingness to have digital photographs taken of the face.
- •Agree not to undergo any other procedure for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea during the study.
- •Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.
排除标准
- •History of prior laser or light based procedures for the face within 6 months of study participation.
- •Fitzpatrick Skin Type IV - VI.
- •Pregnant and/or breastfeeding.
- •Subject is less than 20 years of age or greater than 80 years of age.
- •Having an infection, dermatitis or rash in the treatment area.
- •Suffering from significant concurrent illness, such as diabetes mellitus, cardiovascular disease, uncontrolled hypertension, or pertinent neurological disorders.
- •History of keloid formation, hypertrophic scarring or of abnormal wound healing.
- •History of immunosuppression/immune deficiency disorders such as psoriasis, eczema, vitiligo, or currently using immunosuppressive medications.
- •Malignant tumors in the target area or history of a malignant skin disease.
- •History of fibromyalgia.
- •History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
- •Having a known anticoagulative condition or taking prescription anticoagulation medications.
- •History of seizure disorders due to light.
- •Any current use of medication that is known to increase sensitivity to light, such as tetracycline.
- •Having a history of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area, unless treatment is conducted following a prophylactic regimen.
- •Having undergone any surgery in the treatment area within 6 months of treatment (or more if skin has not healed completely).
- •History of radiation to the head, neck and/or upper chest.
- •History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
- •Undergoing systemic chemotherapy for the treatment of cancer.
- •Systemic use of retinoid such as isotretinoin and/or corticosteroid within 6 months.
- •Topical use of retinoid and/or corticosteroid within 4 weeks of study participation.
- •Any use of gold therapy for disorders such as rheumatologic disease or lupus.
- •Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
- •Current smoker or history of smoking within 12 months of study participation.
- •Participation in a study of another device or drug within 6 months prior to enrollment or during the study.
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
结局指标
主要结局
Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea
时间窗: 6 weeks
Measured for each treatment arm based on blinded physician assessment of subject photographs using the Physician's Global Assessment Scale (min=0; max=4) Higher scores mean better improvement 0 = 0% Improvement (None) 1. = \< 25% Improvement (Mild) 2. = 26 to 50% Improvement (Moderate) 3. = 51 to 75% Improvement (Significant) 4. = 76 to 100% Improvement (Very Significant)
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
A Study of a Laser for the Treatment of Acne VulgarisAcne VulgarisNCT05430464Cutera Inc.30
已完成
不适用
Efficacy of Long Pulsed 1064nm Laser for Facial Skin TighteningSkin TighteningSkin LaxityWrinkle ReductionNCT01971736Phramongkutklao College of Medicine and Hospital22
已完成
不适用
Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of CivattePoikiloderma of CivatteDyschromiaPigmentation DisordersTelangiectasiaPhotosensitivity DisordersNCT01491620Cutera Inc.24
Unknown
不适用
Efficacy of 311-nm Ti:Sapphire Laser Versus 308-nm Excimer Laser Treatment in VitiligoVitiligoNCT02925767The Catholic University of Korea16
已完成
不适用
Study of Picosecond and Nanosecond Q-switched Lasers for Tattoo RemovalTattoo RemovalNCT01973166Cutera Inc.42